Bottom Line:
Quality assessment (assessment of risk of bias) and data synthesis will be implemented using Review Manager (RevMan) software (V.5.2.3).Updates will be conducted if there is enough new evidence that may cause any change in review conclusions.PROSPERO CRD42014013645.

Mentions:
Two reviewers, WZ and WP, will independently determine the eligibility of studies. Duplicates and non-clinical trials will be removed by screening the titles and abstracts. Reviewers will read the full text if they are not sure whether the studies meet the inclusion criteria. Studies will be excluded if they are not truly randomised (Quasi-RCTs) or involve any unqualified interventions. A third party (ZL) will resolve any disagreements. Study selection is summarised in a PRISMA flow diagram (figure 1).

Mentions:
Two reviewers, WZ and WP, will independently determine the eligibility of studies. Duplicates and non-clinical trials will be removed by screening the titles and abstracts. Reviewers will read the full text if they are not sure whether the studies meet the inclusion criteria. Studies will be excluded if they are not truly randomised (Quasi-RCTs) or involve any unqualified interventions. A third party (ZL) will resolve any disagreements. Study selection is summarised in a PRISMA flow diagram (figure 1).

Bottom Line:
Quality assessment (assessment of risk of bias) and data synthesis will be implemented using Review Manager (RevMan) software (V.5.2.3).Updates will be conducted if there is enough new evidence that may cause any change in review conclusions.PROSPERO CRD42014013645.